Valitor (Drug Discovery) Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • University Spin-Out

  • Investors
  • 20

Valitor (Drug Discovery) General Information

Description

Developer of new generation drugs designed to improve the current treatment strategies for a variety of diseases. The company's drugs act within a targeted diseased tissue and modify therapeutic proteins to achieve substantial control over pharmacokinetics, enabling physicians to treat their patients in an enhanced way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2956 San Pablo Avenue
  • Berkeley, CA 94702
  • United States
+1 (510)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2956 San Pablo Avenue
  • Berkeley, CA 94702
  • United States
+1 (510)

Valitor (Drug Discovery) Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Valitor (Drug Discovery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. University Spin-Out 01-Oct-2010 Completed Startup
9. Secondary Transaction - Private 03-Oct-2023 Completed Pre-Clinical Trials
8. Accelerator/Incubator 20-Sep-2023 Completed Pre-Clinical Trials
7. Later Stage VC (Series B) 05-Oct-2022 Completed Pre-Clinical Trials
6. Grant 01-Jul-2021 Completed Pre-Clinical Trials
5. Seed Round 21-Sep-2018 Completed Pre-Clinical Trials
4. Grant 01-Jan-2018 Completed Pre-Clinical Trials
3. Accelerator/Incubator 01-Feb-2018 Completed Pre-Clinical Trials
2. Accelerator/Incubator 28-Oct-2015 $50K $50K Completed Pre-Clinical Trials
1. Grant 01-May-2014 $2.12M Completed Pre-Clinical Trials
To view Valitor (Drug Discovery)’s complete valuation and funding history, request access »

Valitor (Drug Discovery) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Valitor (Drug Discovery)’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Valitor (Drug Discovery) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of new generation drugs designed to improve the current treatment strategies for a variety of diseases. The co
Drug Discovery
Berkeley, CA
15 As of 2024

Boston, MA
 

La Jolla, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Valitor (Drug Discovery) Competitors (2)

One of Valitor (Drug Discovery)’s 2 competitors is Monte Rosa Therapeutics, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Monte Rosa Therapeutics Formerly VC-backed Boston, MA
Inhibrx Formerly VC-backed La Jolla, CA
You’re viewing 2 of 2 competitors. Get the full list »

Valitor (Drug Discovery) Patents

Valitor (Drug Discovery) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230406916-A1 Humanized multivalent protein conjugates Pending 15-Apr-2022
US-20230405133-A1 Purified multivalent protein-hyaluronic acid polymer conjugates Pending 15-Apr-2022
AU-2023254257-A1 Humanized multivalent protein conjugates Pending 15-Apr-2022
AU-2023254113-A1 Purified multivalent protein-hyaluronic acid polymer conjugates Pending 15-Apr-2022
AU-2023252928-A1 Method of treating uveitis with multivalent protein-hyaluronic acid polymer conjugate Pending 15-Apr-2022 C07K14/8114
To view Valitor (Drug Discovery)’s complete patent history, request access »

Valitor (Drug Discovery) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Valitor (Drug Discovery) Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds
5Y Capital Venture Capital Minority
Angel Physicians Fund Angel Group Minority
ExSight Ventures Venture Capital Minority
First Spark Ventures Venture Capital Minority
Morningside Group Venture Capital Minority
You’re viewing 5 of 20 investors. Get the full list »

Valitor (Drug Discovery) FAQs

  • When was Valitor (Drug Discovery) founded?

    Valitor (Drug Discovery) was founded in 2010.

  • Where is Valitor (Drug Discovery) headquartered?

    Valitor (Drug Discovery) is headquartered in Berkeley, CA.

  • What is the size of Valitor (Drug Discovery)?

    Valitor (Drug Discovery) has 15 total employees.

  • What industry is Valitor (Drug Discovery) in?

    Valitor (Drug Discovery)’s primary industry is Drug Discovery.

  • Is Valitor (Drug Discovery) a private or public company?

    Valitor (Drug Discovery) is a Private company.

  • What is Valitor (Drug Discovery)’s current revenue?

    The current revenue for Valitor (Drug Discovery) is .

  • How much funding has Valitor (Drug Discovery) raised over time?

    Valitor (Drug Discovery) has raised $30.6M.

  • Who are Valitor (Drug Discovery)’s investors?

    5Y Capital, Angel Physicians Fund, ExSight Ventures, First Spark Ventures, and Morningside Group are 5 of 20 investors who have invested in Valitor (Drug Discovery).

  • Who are Valitor (Drug Discovery)’s competitors?

    Monte Rosa Therapeutics and Inhibrx are competitors of Valitor (Drug Discovery).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »